問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Dermatology

更新時間：2023-09-19

何宜承
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

29Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

何宜承

List

58Cases

2019-12-01 - 2026-07-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

2022-02-03 - 2022-12-16

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-09-30 - 2027-06-30

Phase II

Active
A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients with Non-segmental Vitiligo

  • Condition/Disease

    Non-segmental Vitiligo

  • Test Drug

    EI-001

Participate Sites
2Sites

Recruiting2Sites

2023-10-01 - 2027-12-31

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-06-30 - 2027-07-28

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Hand and Foot Dermatitis

  • Condition/Disease

    Atopic Hand and Foot Dermatitis

  • Test Drug

    異可適注射劑 (EBGLYSS Injection)

Participate Sites
7Sites

Recruiting7Sites

2024-01-01 - 2025-09-10

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2024-12-01 - 2028-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2034-08-15

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-11-01 - 2030-06-07

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting1Sites

2026-01-05 - 2028-05-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting7Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB